PROTOCOL operates a hybrid care model combining a physical clinic at 71 Robinson Road, Singapore, with a digital-first health platform and proprietary health dashboard currently in beta. The company offers comprehensive screening with advanced bloodwork panels tracking over 100 biomarkers, clinician-supervised GLP-1 weight management therapy, testosterone replacement therapy, targeted supplementation prescribed based on individual bloodwork, and personalised coaching from a dedicated care team of licensed doctors, nutritionists, and health coaches. PROTOCOL's dashboard provides members real-time access to biomarker results, trends, and clinical recommendations, with new features being introduced monthly. The company was founded in September 2025 by Mehdi Elaichouni, who brings prior marketing leadership experience and a personal health-driven mission to the business. PROTOCOL plans to use its pre-seed capital to expand clinical and operations headcount, accelerate product and analytics development, and scale member acquisition across Singapore. The article does not disclose revenue, user metrics, or prior financing beyond the announced pre-seed round.

Total raised

$1M

Funding rounds

1

Latest round

Seed

Latest activity

Apr 2026